| Company Name: | Genomic Health, Incorporated | | Ticker Symbol: | GHDX | | | WWW Address: | www.genomichealth.com | | CEO: | Kimberly J. Popovits | | No. of Employees: | 387 | | Common Issue Type: | CS | | Business Description: | A life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.
|
| | | Industry Information: | HEALTH SERVICES - Medical Laboratories & Research [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 19.38 |  0.09 | 18.74 | 20.2 | 19.49 | 19.76 | 19.24 | 57504 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 554.3 | 28.6 | 0.69 | -0.57 | 0.00 | 0.0 | 0.0 | 27.22 - 15.81 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 19.38 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 553.5 | mil |
| Latest Shares Outstanding | 28.6 | mil |
| Earnings pS (EPS) | -0.57 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 285,734 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 25.5 | mil |
| Float as % of Shares Outstanding | 89.3 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 61.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 24.80 | % |
| Gross Profit Margin | 82.3 | % |
| EBITDA Margin | -3.9 | % |
| Pre-Tax Profit Margin | -7.8 | % |
| Assets Turnover | 1.6 | % |
| Return on Assets (ROA) | -12.9 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -17.3 | % |
| Current Ratio | 3.5 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.01 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 1.86 | $ |
| Cash pS | 0.59 | $ |
| Book-Value pS | 2.30 | $ |
| Tangible Book-Value pS | 2.30 | $ |
| Cash Flow pS | -0.18 | $ |
| Free Cash Flow pS | 0.18 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 8.42 | |
| Price/Tangible Book Ratio | 8.42 | |
| Price/Cash Flow | -108.2 | |
| Price/Free Cash Flow | 109.3 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.5 | 99 | 906 | 556 |
| 4 Weeks | 20.79 | 18.31 | 18.57 | 4.4 | 98 | 1,089 | 17,417 |
| 13 Weeks | 22.00 | 18.29 | 20.04 | -3.3 | 90 | 1,050 | 63,003 |
| 26 Weeks | 22.00 | 15.81 | 19.40 | -0.1 | 83 | 1,292 | 160,267 |
| 52 Weeks | 27.22 | 15.81 | 18.53 | 4.6 | 85 | 1,518 | 376,454 |
| YTD | 27.22 | 15.81 | - | -0.5 | 81 | 1,553 | 350,927 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 19.25 | 19.42 | 20.19 | 19.04 | 19.86 | 0.69 | 0.56 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 0.00 | 0.0 | 69.05 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 0.00 | NA | 36.57 |
| R&D | 0.00 | NA | 40.43 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 38.6 | 40.5 | 72.7 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 0.17 | 0.09 | 0.45 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 60.78 |
| Current Ratio | 4.0 |
| Quick Ratio (Acid Test) | 3.7 |
| Liquidity Ratio (Cash) | 3.23 |
| Receivables Turnover | 15.9 |
| Average Collection Period | 23 |
| Working Capital/Equity | 79.6 |
| Working Capital pS | 1.85 |
| Cash-Flow pS | -0.39 |
| Free Cash-Flow pS | -0.38 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 17.36 |
| Financial Leverage Ratio (Assets/Equity) | 1.3 |
| Debt Ratio | 23.7 |
| Total Debt/Equity (Gearing Ratio) | 0.03 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 4.4 |
| LT Debt/Total Liabilities | 1.1 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.56 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 7.77 |
| Tobin's Q Ratio | 6.38 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -41.37 |
| Enterprise Value (EV)/Free Cash Flow | -55.85 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 8.42 |
| Price/Book Ratio - LTM | 8.42 |
| Price/Cash Flow Ratio | -108.2 |
| Price/Free Cash Flow Ratio - LTM | 109.3 |
| Price/Sales Ratio | 3.92 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.01 |
| Current Liabilities pS | 0.62 |
| Tangible Book Value pS - LTM | 2.30 |
| Book Value pS - LTM | 2.30 |
| Capital Invested pS | 2.33 |
| Cash pS - LTM | 0.59 |
| Cash Flow pS - LTM | -0.18 |
| Free Cash Flow pS - LTM | 0.18 |
| Earnings pS (EPS) | -0.57 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -9.83 |
| Free Cash Flow Margin 5YEAR AVG | -1,673.96 |
| Net Profit Margin | -14.5 |
| Net Profit Margin - 5YEAR AVRG. | -61.5 |
| Equity Productivity | 1.67 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 1.67 |
| Return on Capital Invested (ROCI) | -24.2 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -67.0 |
| Assets Productivity | 1.30 |
| Return on Assets (ROA) | -18.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | -36.8 |
| Gross Profit Margin | 82.3 |
| Gross Profit Margin - 5YEAR AVRG. | 77.5 |
| EBITDA Margin - LTM | -3.9 |
| EBIT Margin - LTM | -7.7 |
| Pre-Tax Profit Margin | -14.6 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -61.5 |
| Effective Tax Rate | 0.4 |
| Effective Tax Rate - 5YEAR AVRG. | 0.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 29 |
| Revenue per Employee | 285,734 |
| Net Income per Employee | -41,574 |
| Average Collection Period | 29 |
| Receivables Turnover | 15.9 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 3.36 |
| Assets/Revenue | 0.77 |
| Net Working Capital Turnover | 2.10 |
| Fixed Assets Turnover | 6.73 |
| Total Assets Turnover | 1.3 |
| Revenue per $ Cash | 9.90 |
| Revenue per $ Plant | 7.11 |
| Revenue per $ Common Equity | 1.67 |
| Revenue per $ Capital Invested | 1.67 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 65.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 95.3 |
| Research & Devlopment (R&D) as % of Revenue | 25.9 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 25.9 |
|
|  
|
| |
 |  |